Lantern Pharma

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantern Pharma reports robust Q4 earnings, unveils strategic drug plans

Lantern Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic drug development plans, and a focus on innovation.
The company faces challenges in a competitive landscape but has opportunities in combination therapies, CNS cancer treatments, and engaging key opinion leaders.
Effective financial management and a clear clinical development roadmap are key strengths for Lantern Pharma.
Balancing financial stability with continued investment in research and development will be crucial for sustained growth.

Lantern Pharma advances AI-driven drug development with strong financial backing

Lantern Pharma's Q1 2023 Earnings Call highlighted significant progress in drug development and financial stability, underpinned by a focus on AI and data analytics.
While facing challenges in managing R&D expenses and industry competition, the company's innovative approach and strong cash position position them well for future growth.
Opportunities abound for Lantern Pharma to further leverage AI, explore partnerships, and advance in critical areas like brain cancer drug discovery.
Overall, Lantern Pharma's strategic focus on technology-driven efficiency and innovation sets a promising trajectory for their future in the pharmaceutical landscape.

Lantern Pharma reports promising Q2 results amidst AI-driven advancements

Lantern Pharma's Q2 2023 performance reflects a mix of financial stability, promising drug candidates, and advancements in AI-driven drug development.
The company's strengths lie in its innovative AI-driven strategy, focus on biology, and cost-effective approach to advancing molecules into trials.
Challenges include optimizing trial enrollment, addressing clinician preferences, and navigating the competitive landscape of AI-driven drug discovery.
Opportunities for Lantern Pharma include presenting new data, exploring combination therapies, and leveraging their fit-for-purpose strategy in oncology for future growth.

Lantern Pharma reports Q3 progress, financial stability, and innovation focus

Lantern Pharma's Q3 2023 earnings call highlighted progress in drug development, financial stability with a cash runway into at least Q3 2025, and a focus on innovation through the RADR platform.
While facing challenges such as a net loss and the need to improve financial performance, the company's strengths in pipeline development and technological innovation position them for future growth.
Opportunities lie in leveraging the RADR platform for accelerated drug development, data accumulation in 2024, and pursuing strategic initiatives supported by a strong cash position.
Overall, Lantern Pharma's earnings call reflects a balance of achievements, challenges, and opportunities that shape their trajectory in the pharmaceutical industry.

Lantern Pharma reports Q4 loss, eyes collaborations for growth

Lantern Pharma's Q4 2023 performance reflects a focus on innovation and strategic financial management.
The company's strengths lie in AI-driven drug discovery, diversification efforts, and platform advancements.
Challenges include managing expenses, navigating risks, and ensuring successful execution of growth plans.
Opportunities in collaborations, licensing, and leveraging their platform as a currency offer avenues for expansion.

Lantern Pharma reports Q1 loss, advances AI drug development

Lantern Pharma's Q1 2024 earnings call highlighted financial results, AI-driven drug development, and collaborations.
The company's focus on accelerating drug development and expanding into new indications shows promise for future growth.
Despite challenges in timelines and trial expansions, Lantern Pharma aims for more efficient drug development processes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the second quarter ended June 30, 2023. "We made significant strides over the past quarter in executing our mission of transforming the oncology drug discovery and.

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

Remark Hlds

SoundHound AI Inc

As we forge ahead into the AI era, the top AI penny stocks have become increasingly relevant, emerging as a buzzword among savvy investors. Projected to inject a massive $15.7 trillion into the global economy by the conclusion of the current decade, AI is no longer just the playground for large-cap tech giants.

3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True

AbCellera Biologics

Recursion Pharmaceuticals

Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI stocks to invest in. At the moment, new drug development has a ridiculous fail rate of 90%, according to the National Institutes of Health.

3 AI Stocks You'll Regret Not Buying Soon

Amesite Operating

GSI Technology

ShiftPixy

Veritone

Let's take a look at some of the top AI stocks in August 2023. For the most part, the average investor is familiar with the major names in the sector, such as  Nvidia (NASDAQ: NVDA ) and Microsoft (NASDAQ: MSFT ).

7 AI Stocks to Buy Under $5 in August 2023

Bullfrog AI Holdings Inc

Reviva Pharmaceuticals

Sharps Technology Inc

Zomedica

New podcast series shines a spotlight on undervalued small-cap and microcap stocks ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money." Hosted by RedChip CEO Dave Gentry and Associate Director Barrett Boone, the "Small Stocks, Big Money" podcast aims to offer a first-hand look at undiscovered small-cap and microcap stocks before they catch the attention of bigger Wall Street players.

RedChip Launches 'Small Stocks, Big Money' Podcast

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its second quarter 2023 operating and financial results webcast on Wednesday, August 9, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET

Predictive Oncology Inc

Rekor Systems Inc

The bull market in artificial intelligence is just getting started. In fact, with the boom only set to accelerate, we may be looking at a $1.81 trillion opportunity by 2030, says Grand View Research.

3 AI Stocks to Buy Under $10 in August 2023

Ideanomics Inc

The era of artificial intelligence is upon us. By 2030, AI is expected to contribute $15.7 trillion to the global economy.

7 AI Penny Stocks that Could Hit $5 Soon

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that the Company will participate and present at four upcoming conferences: Biotech CEO Summit USA in La Jolla, CA from July 17-19, 2023. Panna Sharma, Lantern's CEO and President will be participating. Conferenc.

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced the company has published new findings in Oncotarget demonstrating drug candidate LP-284's in vitro and in vivo antitumor potency for multiple non-Hodgkin's lymphomas (NHL), including mantle cell lymphoma (MCL) a.

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin's Lymphomas

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS).

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will be leveraging its AI platform, RADR®, in a research collaboration with Bielefeld University (Bielefeld, Germany) to develop antibody-drug conjugates (ADCs) with high therapeutic and antitum.

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

Oblong

OneConnect Financial Tech Co Ltd ADR

AI penny stocks offer investors a thrilling opportunity to tap into the fast-evolving artificial intelligence space. AI penny stocks have limited financial resources and modest profits, but their long-term growth prospects are enticing.

3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, CEO and President, will present at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023. The fireside chat-style webcast will be available to all registe.

Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET

Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Conference Call Participants Michael King - EF Hutton Nicole Leber Good afternoon, everyone. I'm Nicole Weber with Investor Relations here at Lantern Pharma.

Lantern Pharma Inc. (LTRN) Q1 2023 Earnings Call Transcript

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the first quarter ended March 31, 2023. “This quarter we continued to execute our mission of transforming the oncology drug discovery and developmen.

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

BELTSVILLE, Md. , May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)".

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its first quarter 2023 operating and financial results webcast on Tuesday, May 9, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating.

Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has developed highly-accurate and industry-leading AI algorithms to predict the ability of a drug or compound to pass the blood-brain-barrier (BBB), a highly selective border that can preve.

Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. patent application no.

Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc.

Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management and employees will be presenting at three upcoming events: Rare Disease Innovation & Partnership Summit in Philadelphia, PA on Wednesday, March 22 at 5:00 p.m. ET.

Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2022 Results Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Nicole Leber - Investor Relations Associate Panna Sharma - Chief Executive Officer and President David Margrave - Chief Financial Officer and Secretary Kishor Bhatia - Chief Scientific Officer Conference Call Participants John Vandermosten - Zacks Research Michael King - EF Hutton Nicole Leber Welcome to our fourth quarter and full-year 2022 earnings call. I will be your host for today's call.

Lantern Pharma Inc. (LTRN) Q4 2022 Earnings Call Transcript

The stock price of Lantern Pharma Inc (NASDAQ: LTRN) increased by 7.74% after hours in the most recent trading session. This is why.

LTRN Stock: 7.74% Increase After Hours Explanation

DALLAS--(BUSINESS WIRE)---- $LTRN--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.

News for Lantern Pharma Stock (LTRN)